Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Transgene

Transgene?uq=kzBhZRuG
1979 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
TNG STOCK SYMBOL
1 INVESTMENTS
$3.55 SHARE PRICE (As of Friday Closing)
Description

Developer of immunotherapies for the treatment of cancer. The company is engaged in developing a pipeline of immunotherapy treatments solid tumors, non-small cell lung cancer, Hepatocellular carcinoma, Chronic hepatitis B and tuberculosis.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 400 Boulevard Gonthier d'Andernach
  • Parc d'Innovation
  • 67405 Illkirch-Graffenstaden Cedex
  • France

+33 03 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Transgene’s full profile, request a free trial.

Transgene Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.89 - $4.23 $219M $3.53 -$0.59 63.9K 62.1M

Transgene Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 234,017 234,017 115,852 130,237
Revenue 8,410 8,410 9,654 10,611
EBITDA (33,473) (33,473) (23,538) (38,751)
Net Income (36,397) (36,397) (27,883) (51,444)
Total Assets 121,018 121,018 129,307 110,280
Total Debt 73,972 73,972 65,759 58,222
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Transgene Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Transgene‘s full profile, request access.

Request full access to PitchBook

Transgene Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000 (0 01-Jan-2010 00000 0000000 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Transgene Executive Team (4)

Name Title Board
Seat
Contact
Info
Philippe Archinard Ph.D Chief Executive Officer & Chairman
Eric Quéméneur Ph.D Executive Vice President & Vice President, Research & Development
Thibaut Du Fayet Vice President, Alliance Management, Project Management & Marketing
Maud Brandely Ph.D Chief Medical Officer

Transgene Board Members (10)

Name Representing Role Since Contact
Info
00000 0é00000 Self Board Member 000 0000
0000000 0é000 Transgene Independent Director & Chairman of the Compensation Committee 000 0000
000000 000000 Self Independent Director & Chairman, Compensation Committee 000 0000
0000-0000ç000 0000é Self Board Member 000 0000
0000-000 0é0000000 Transgene Director 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »